Testing av svulstvev og blod for å hjelpe til med å velge tilpassede behandlinger for pasienter med mistenkt lungekreft
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluering av handlingsdyktige drivere i tidlig stadium av lungekreft
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.
The primary purpose of this testing is to determine the presence of 12 oncogenic drivers (mutations in EGFR, BRAFV600E , MET exon 14, KRAS G12C and HER2, rearrangements in ALK, RET, NTRK, EGFR exon 20 insertion and ROS1, and amplification of MET and HER2) that can serve as targets making patients eligible for upcoming targeted neoadjuvant therapy trials. The ultimate goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected.
Thoracic Surgery Oncology Group (TSOG) is a network of surgeons within North American Thoracic Surgery Academic Centers aligned with the goal of enhancing patient care through administration of multi-site trials focused on recent advances in lung cancer. TSOG has aligned with the LCMC4 sites to enroll the LCRF-LEADER screening trial. TSOG's involvement will be essential in trial enrollment and ultimate interpretation of the multimodal clinical and translational data collected as part of this study. We estimate we will detect an actionable oncogenic driver in 33% of cases. The remaining 66% of patients will represent a cohort identified by their care teams as candidates for other potential neoadjuvant therapies which may include checkpoint inhibitors such as atezolizumab, durvalumab, nivolumab, and pembrolizumab or other novel agents.
The targeted therapy treatment trials will be conducted independently of the LCRF-LEADER screening trial, evaluating for efficacy. If none of the 10 oncogenic drivers are detected, the patient will be offered participation in any clinical trial of neoadjuvant therapy available at their treating institution or standard of care therapy. For patients not enrolled on a targeted treatment trial, circulating tumor DNA in blood (ctDNA) will be collected at 3 time points: before neoadjuvant treatment, after neoadjuvant treatment but before surgery, and after surgery. This initiative will be correlated with various clinical outcomes. Prespecified clinical data will be collected for correlation with these circulating biomarkers.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Christian Brodala, BBA
- Telefonnummer: 646-608-2838
- E-post: brodalac@mskcc.org
Studiesteder
-
-
California
-
Davis, California, Forente stater, 95616
- Aktiv, ikke rekrutterende
- University of California, Davis
-
Los Angeles, California, Forente stater, 90095
- Aktiv, ikke rekrutterende
- UCLA
-
Los Angeles, California, Forente stater, 90033
- Tilbaketrukket
- USC Norris Comprehensive Cancer Center
-
Orange, California, Forente stater, 92868
- Rekruttering
- St. Joseph's Hospital Orange
-
Ta kontakt med:
- Ron Bati
- E-post: Ron.Bati@stjoe.org
-
Hovedetterforsker:
- Tiimothy Byun, MD
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford University
-
Ta kontakt med:
- Debbie Bajomo
- E-post: bajomo@stanford.edu
-
Hovedetterforsker:
- Douglas Liou, MD
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Rekruttering
- Hartford Healthcare
-
Ta kontakt med:
- Lorin Campos
- E-post: lorin.campos@hhchealth.org
-
Ta kontakt med:
- Corey Glider
- E-post: Corey.Glider@hhchealth.org
-
Hovedetterforsker:
- Brian Whang, MD, FACS
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Hovedetterforsker:
- Andreas Saltos, MD
-
Ta kontakt med:
- Tara Ackerman
- E-post: Tara.Ackerman@moffitt.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University
-
Hovedetterforsker:
- Jyoti Patel, MD
-
Ta kontakt med:
- RHLCCC Trial Team
- E-post: RHLCCCTrialStartup@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Brigham and Women's Hospital
-
Ta kontakt med:
- Kristina Sidopoulos
- E-post: ksidopoulos@bwh.harvard.edu
-
Hovedetterforsker:
- Hisashi Tsukada, MD, PhD
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Hovedetterforsker:
- Michael Lanuti, MD
-
Ta kontakt med:
- Isha Mehta Warikoo
- E-post: imehtawarikoo@mgh.harvard.edu
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Hovedetterforsker:
- David Kwiatkowski, MD
-
Ta kontakt med:
- Jennifer Luu
- E-post: jennifer_luu@dfci.harvard.edu
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
Ta kontakt med:
- Christine Conley
- E-post: Cconley@bidmc.harvard.edu
-
Hovedetterforsker:
- Sidhu Gangadharan, MD
-
Boston, Massachusetts, Forente stater, 02118
- Rekruttering
- Boston Medical Center
-
Ta kontakt med:
- Anthony Shelton
- E-post: anthony.shelton@bmc.org
-
Hovedetterforsker:
- Umit Tapan, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Rekruttering
- University of Michigan
-
Ta kontakt med:
- Shari Barnett
- E-post: shbailey@med.umich.edu
-
Hovedetterforsker:
- Jules Lin, MD
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65212
- Rekruttering
- University of Missouri
-
Ta kontakt med:
- Brooke McDaniel
- E-post: mcdanielbl@health.missouri.edu
-
Hovedetterforsker:
- Jussuf Kaifi, MD
-
St Louis, Missouri, Forente stater, 63110
- Aktiv, ikke rekrutterende
- Washington University
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Rekruttering
- Dartmouth-Hitchcock
-
Ta kontakt med:
- Kristina Wiley
- E-post: Kristina.M.Willey@hitchcock.org
-
Hovedetterforsker:
- David Finley, MD
-
-
New York
-
New York, New York, Forente stater, 10032
- Aktiv, ikke rekrutterende
- Columbia University
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU
-
Hovedetterforsker:
- Elaine Shum, MD
-
Ta kontakt med:
- Nadia Catti
- E-post: nadia.catti@nyulangone.org
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- Ohio State University
-
Ta kontakt med:
- Helena Gastier
- E-post: Helena.gastier@osumc.edu
-
Hovedetterforsker:
- Desmond D'Souza, MD
-
-
Oregon
-
Portland, Oregon, Forente stater, 97213
- Rekruttering
- Providence Portland
-
Hovedetterforsker:
- Rachel Sanborn, MD
-
Ta kontakt med:
- Brenda Fisher
- E-post: brenda.fisher@providence.org
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Ta kontakt med:
- Jessica Shealor
- E-post: shealorj@musc.edu
-
Hovedetterforsker:
- Ian Bostock, MD
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Ta kontakt med:
- Michelle Almarez
- E-post: michelle.almarez@bcm.edu
-
Hovedetterforsker:
- Taylor Ripley, MD
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Virginia Cancer Specialists, PC
-
Hovedetterforsker:
- Alexander Spira, MD, PhD, FACP
-
Ta kontakt med:
- Brian Phipps
- E-post: Brian.phipps@usoncology.com
-
-
Washington
-
Seattle, Washington, Forente stater, 98019
- Rekruttering
- University of Washington
-
Ta kontakt med:
- Lara Schiff
- E-post: lschiff1@seattlecca.org
-
Hovedetterforsker:
- Christina Baik, MD, MPH
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The LCMC LEADER screening trial will enroll all patients with clinically suspected, resectable stage I-III lung cancers. The population of interest is patients with resectable non-squamous non-small cell lung cancer, however a histologic diagnosis is not required at the time of study enrollment. We anticipate a small portion of patients with squamous cell and non-NSCLC histologies to be genotyped centrally in parallel to their histologic diagnosis. Only patients with non-small cell lung cancers that are not purely squamous will be counted towards the primary study endpoint.
Beskrivelse
Inclusion Criteria:
- Clinical stage IA2-III lung cancers
- Potentially resectable if lung cancer suspicion confirmed pathologically
- Operable
Exclusion Criteria:
- No concurrent malignancy
- No prior lung cancer within last 2 years
- Purely ground glass pulmonary opacity
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Patients who Possess Actionable Oncogenic Drivers
Tidsramme: 8 weeks
|
The primary outcome measure is the determination of the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. A patient is considered to have a actionable oncogenic driver if they have any of the following 10 genomic alterations: ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, or ROS1 rearrangements. |
8 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Tumor Mutation Burden (TMB) Assessment
Tidsramme: 8 weeks
|
Measure TMB in all patient tumor samples (Mutations per megabase) |
8 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Michael Lanuti, MD, Massachusetts General Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- LCMC LEADER
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .